• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Passage Bio Inc.

    3/5/25 6:05:54 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PASG alert in real time by email
    S-8 1 tm258209d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 5, 2025

    Registration No. 333-

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

    PASSAGE BIO, INC.
    (Exact name of Registrant as specified in its charter)

     

    Delaware 82-2729751
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification Number)

     

    One Commerce Square
    2005 Market Street, 39th Floor
    Philadelphia, Pennsylvania, 19103
    (Address of Principal Executive Offices) (Zip Code)

     

    2020 Equity Incentive Plan
    (Full title of the plans)

     

    William Chou, M.D.

    Chief Executive Officer

    Passage Bio, Inc.

    One Commerce Square

    2005 Market Street, 39th Floor

    Philadelphia, PA 19103
    (Name and Address of Agent for Service)

     

    (267) 866-0311
    (Telephone number, including area code, of agent for service)

     

    Please send copies of all communications to:

    Effie Toshav, Esq.

    Robert A. Freedman, Esq.

    Ryan Mitteness, Esq.

    Fenwick & West LLP

    401 Union Street, 5th Floor

    Seattle, Washington 98101

    (206) 389-4510

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer ¨ 
    Non-accelerated filer x   Smaller reporting company x 
          Emerging growth company x 

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    REGISTRATION OF ADDITIONAL SHARES
    PURSUANT TO GENERAL INSTRUCTION E

     

    Passage Bio, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register 3,103,089 additional shares of common stock available for issuance under the Registrant’s 2020 Equity Incentive Plan (the “2020 EIP”), pursuant to the provision of the 2020 EIP providing for an annual 5% automatic increase in the number of shares reserved for issuance.

     

    In accordance with General Instruction E of Form S-8, and only with respect to the common stock issuable under the 2020 EIP, this Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statements on Form S-8 filed with the Commission on February 27, 2020 (Registration No. 333-236734), March 5, 2021 (Registration No. 333-253922), March 3, 2022 (Registration No. 333-263252), March 6, 2023 (Registration No. 333-270293), and March 4, 2024 (Registration No. 333-277637) to the extent not superseded hereby.

     

     2 

     

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents filed by the Registrant with the Commission pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

    (a)the Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 4, 2025 pursuant to Section 13 of the Exchange Act;

     

    (b)all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report on Form 10-K referred to in (a) above; and

     

    (c)the description of the Registrant’s common stock contained in the Registrant’s registration statement on Form 8-A (File No. 001-39231) filed with the Commission on February 18, 2020 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

     

    All documents and definitive proxy or information statements filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission. Unless expressly incorporated into this Registration Statement, a report deemed to be furnished but not filed on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

     

     3 

     

     

    Item 8. Exhibits

     

    The following exhibits are filed herewith:

     

        Incorporated by Reference Filed
    Herewith
    Exhibit
    Number
    Exhibit Description Form File No. Exhibit Filing Date
    4.1 Restated Certificate of Incorporation, dated May 30, 2023 10-Q 001-39231 3.1 August 7, 2023  
    4.2 Amended and Restated Bylaws, dated December 1, 2022 8-K 001-39231 3.1 December 2, 2022  
    4.3 Form of Registrant’s Common Stock certificate S-1/A 333-236214 4.1 February 18, 2020  
    5.1 Opinion of Fenwick & West LLP         X
    23.1 Consent of Fenwick & West LLP (contained in Exhibit 5.1)         X
    23.2 Consent of Independent Registered Public Accounting Firm         X
    24.1 Power of Attorney (including on the signature page to this Registration Statement)         X
    99.2 2020 Equity Incentive Plan and forms of award agreements thereunder S-1/A 333-236214 10.3 February 18, 2020  
    107.1 Calculation of Registration Fees         X

     

     4 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Philadelphia, Commonwealth of Pennsylvania, on this 5th day of March, 2025.

     

      PASSAGE BIO, INC.
       
      By: /s/ WILLIAM CHOU
        William Chou M.D.
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints William Chou, M.D., Kathleen Borthwick and Edgar B. Cale, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the date indicated.

     

    Name   Title   Date
             
    /s/ WILLIAM CHOU   Chief Executive Officer and Director   March 5, 2025
    William Chou, M.D.   (Principal Executive Officer)    
             
    /s/ KATHLEEN BORTHWICK   Chief Financial Officer   March 5, 2025
    Kathleen Borthwick   (Principal Accounting and Financial Officer)    
             
    /s/ MAXINE GOWEN   Chair of the Board of Directors   March 5, 2025
    Maxine Gowen, Ph.D.        
             
    /s/ ATHENA COUNTOURIOTIS   Director   March 5, 2025
    Athena Countouriotis, M.D.        
             
    /s/ SAQIB ISLAM   Director   March 5, 2025
    Saqib Islam        
             
    /s/ SANDIP KAPADIA   Director   March 5, 2025
    Sandip Kapadia        
             
    /s/ DERRELL PORTER   Director   March 5, 2025
    Derrell D. Porter, M.D.        
             
    /s/ DOLAN SONDHI   Director   March 5, 2025
    Dolan Sondhi, Ph.D.        
             
    /s/ THOMAS KASSBERG   Director   March 5, 2025
    Thomas Kassberg        

     

     5 

     

    Get the next $PASG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PASG

    DatePrice TargetRatingAnalyst
    11/29/2024$3.00 → $4.00Outperform
    Wedbush
    9/3/2024$7.00Buy
    Rodman & Renshaw
    3/8/2022Overweight → Neutral
    JP Morgan
    3/4/2022$29.00 → $24.00Outperform
    Raymond James
    1/19/2022$29.00 → $6.00Buy → Neutral
    Goldman
    7/1/2021$29.00Outperform
    Raymond James
    More analyst ratings

    $PASG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

      Treated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated for trial eligibility Announced presentation of process development data of a high productivity, suspension-based manufacturing process for PBFT02 at American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting Cash runway into 1Q 2027 PHILADELPHIA, May 13, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent bu

      5/13/25 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

      Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02, 50% lower than Dose 1 Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 Extended cash runway into 1Q 2027 PHILADELPHIA, March 04, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative d

      3/4/25 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio to Participate in Upcoming Investor Conferences

      PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care ConferenceFormat: Management will participate in a presentation and investor meetingsDate: Wednesday, March 5, 2025Presentation Time: 9:10 a.m. ETLocation: Boston, MA Leerink Global Biopharma Conference Format: Management will participate in a presentation and investor meetingsDate: Wednesday, March 12, 2025Presentation Time: 8:00 a.m. ETLocation: Miami, FL A live web

      2/26/25 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Financials

    Live finance-specific insights

    See more
    • Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

      Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated progranulin levels were sustained at up to six months post-treatmentDose 1 of PBFT02 was generally well-tolerated in patients who received an enhanced steroid regimen for immunosuppression Pipeline to focus on continued advancement of PBFT02 in FTD-GRN and explore PBFT02 in multiple additional adult neurodegenerative diseases Pursuing potential partnership opportunities for clinical-stage pediatric lysosomal storage disease programs including GM1 gangliosidosisManagement to host a webcast presentation to review interim FTD data today at 8:30 a.m. ET

      12/20/23 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study

      Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF biomarkers and was able to achieve normal levels of CSF β-Gal activity and GM1 gangliosides, similar to healthy controlsDose 2 biomarker responses demonstrated durability up to 12 months after treatmentImagine-1 study participants showed initial evidence of improved survival relative to natural history dataTreated first patient at highest dose level, Dose 3, in July; initial safety and biomarker data from Dose 3 expected by mid-2024Management to host a conference call and webcast today at 8:30 a.m. ET

      8/7/23 7:00:12 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

      Presented additional interim data at 19th Annual WORLDSymposium™ showing PBGM01 continued to demonstrate a biological effect in first six patients in Imagine-1 study for GM1 gangliosidosis; initial safety and biomarker data from Cohort 4 expected in mid-2023Planned expansion of Imagine-1 study to treat patients at a higher dose; expect to dose first patient in second half of 2023Plan to report initial safety and biomarker data from Cohort 1 of global upliFT-D trial for frontotemporal dementia in the second half of 2023Ended 2022 with strong cash position; cash runway into the first half of 2025Management to host conference call today at 8:30 a.m. ET PHILADELPHIA, March 06, 2023 (GLOBE NEW

      3/6/23 7:00:41 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush resumed coverage on Passage BIO with a new price target

      Wedbush resumed coverage of Passage BIO with a rating of Outperform and set a new price target of $4.00 from $3.00 previously

      11/29/24 7:25:55 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on Passage BIO with a new price target

      Rodman & Renshaw initiated coverage of Passage BIO with a rating of Buy and set a new price target of $7.00

      9/3/24 8:12:19 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio downgraded by JP Morgan

      JP Morgan downgraded Passage Bio from Overweight to Neutral

      3/8/22 5:15:06 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Lynx1 Capital Management Lp bought $241,038 worth of shares (373,645 units at $0.65) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      12/31/24 4:05:36 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Lynx1 Capital Management Lp bought $146,665 worth of shares (259,998 units at $0.56) and bought $137,855 worth of shares (196,355 units at $0.70) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      11/27/24 6:11:20 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Leadership Updates

    Live Leadership Updates

    See more
    • Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

      Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from Cohort 1 FTD-GRN showed PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months following treatment Highlighted robust preclinical data supporting PBFT02 as a potential best-in-class progranulin-raising therapy in an oral presentation at ESGCT Execution backed by strong balance sheet, with cash runway to the end of Q2 2026 PHILADELPHIA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines comp

      11/13/24 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Welcomes Tom Kassberg to Board of Directors

      PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases. "We are pleased to welcome Tom Kassberg to the Passage Bio Board of Directors, where he will play an influential role in driving our mission

      9/10/24 7:52:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

      Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF biomarkersDose 2 of PBGM01 was able to achieve healthy control levels of CSF β-Gal activity and GM1 gangliosides, with response durable up to 12 months Treated first patient at Dose 3 in Imagine-1 clinical trial in July 2023; initial safety and biomarker data from Dose 3 patients expected by mid-2024Expect to present initial safety and biomarker data from Cohort 1 in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment frontotemporal dementia (FTD) with granulin mutations (GRN) in Q4 202

      8/7/23 7:15:54 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kapadia Sandip

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      5/30/25 9:41:02 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gowen Maxine

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      5/30/25 7:31:13 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Countouriotis Athena

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      5/30/25 7:30:26 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    SEC Filings

    See more
    • Passage Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Passage BIO, Inc. (0001787297) (Filer)

      5/30/25 4:25:09 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Passage Bio Inc.

      10-Q - Passage BIO, Inc. (0001787297) (Filer)

      5/13/25 7:15:28 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Passage BIO, Inc. (0001787297) (Filer)

      5/13/25 7:00:17 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Passage Bio Inc.

      SC 13G - Passage BIO, Inc. (0001787297) (Subject)

      11/14/24 12:03:11 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Passage Bio Inc.

      SC 13D/A - Passage BIO, Inc. (0001787297) (Subject)

      8/9/24 7:06:55 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Passage Bio Inc.

      SC 13G/A - Passage BIO, Inc. (0001787297) (Subject)

      8/9/24 5:15:23 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care